Teresa Carvalho, MS, science writer —

Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.

Articles by Teresa Carvalho

Soliris Treats Rare Case of aHUS Due to Scleroderma Renal Crisis

Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis — a life-threatening complication of an autoimmune disorder that can lead to kidney failure. His case was described in the study, “Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis…

Soliris Effective in aHUS Patients With or Without High Blood Pressure

Soliris (eculizumab) shows effectiveness in treating patients with atypical hemolytic uremic syndrome (aHUS) both with and without severe and life-threatening hypertension, or high blood pressure, a large retrospective study found. Further, the researchers noted, “the results confirm the high [worse] severity and poor prognosis of untreated aHUS,” with a…

Personalized Soliris Regimen Prevented Recurrence, Reduced Costs

Soliris (eculizumab) maintenance therapy administered every three weeks — instead of the biweekly standard regimen — was sufficient to normalize blood parameters and prevent disease recurrence for at least three years in a 4-year-old boy with atypical hemolytic uremic syndrome (aHUS), a case study reported. Individualized Soliris dosing was…

#RAREis Representation Program Promotes Equity, Diversity

Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…